The pathway and the efficiency of intracellular trafficking of Shiga toxin differ between cell types, and this impacts on susceptibility to cytotoxicity. Warnier et al. demonstrate that in cell types targeted during human disease, Shiga toxin undergoes retrograde transport via the trans-Golgi network to the endoplasmic reticulum, albeit less efficiently than in HeLa cells.
Th e Shiga toxins (Stxs) are a distinct family of AB 5 cytotoxins produced by certain strains of Escherichia coli and related enterobacteria. The toxins comprise a catalytic A subunit that is an RNA-Nglycosidase capable of cleaving a critical adenine base from 28S ribosomal RNA, thereby inhibiting the elongation step of eukaryotic protein synthesis. Th e pentameric B subunit is responsible for binding to a specifi c glycolipid receptor (Gb 3 ) on the surface of target cells, triggering internalization of the receptor-holotoxin complex. A landmark study by Karmali et al. 1 established a causal link between gastrointestinal infection with Shiga toxigenic E. coli and hemolytic-uremic syndrome, a potentially life-threatening condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Th e primary insult in hemolytic-uremic syndrome is Stx-mediated damage to microvascular endothelial cells, particularly in the kidney, initiating the coagulation cascade.
During Shiga toxigenic E. coli infection, Stx released into the gut lumen is translocated across the intestinal epithelium into the underlying tissues and bloodstream and then targets host cells expressing Gb 3 .
In humans, high concentrations of Gb 3 are found in renal tubular cells and microvascular endothelial cells, particularly those in the kidney, gut, and brain, consistent with the clinical manifestations of disease. Interestingly, not all Gb 3 -expressing cell types are equally susceptible to Stx, and it is becoming increasingly apparent that differences in toxin trafficking within these cells determine the outcome of the interaction.
Studies of traffi cking of Stx in highly susceptible immortalized cell lines showed that after binding to Gb 3 , the toxin is internalized by receptor-mediated endocytosis. Briefl y, this involves the formation of a clathrin-coated pit within the cell membrane, which pinches off to form early endosomes, with toxin bound to the internal surface. From here it is transported directly to the trans-Golgi network, bypassing late endosomes, and then via the Golgi apparatus to the endoplasmic reticulum (ER) 2 (Figure 1 ). Th is retrograde transport appears to require association of receptor-holotoxin complexes with lipid rafts, which are specialized membrane microdomains rich in cholesterol and glycosphingolipids. Association of toxin with these raft s may be facilitated by the cross-linking of multiple glycolipids by the pentameric B subunit. Th is then enables the toxin to exploit the membrane recycling pathway within the cell, which is essential for retrograde transport. Indeed, experimental destabilization of lipid raft s by extraction of cholesterol has a severe inhibitory eff ect on traffi cking of Stx from early endosomes to the Golgi. 3 Once Stx has reached the ER, the catalytic A subunit (StxA) must be translocated across the ER membrane, and during this step, it is nicked by furin. Th e major A 1 fragment is subsequently released into the cytosol, where it can reach its substrate (28S ribosomal RNA) and exert its cytotoxic eff ects ( Figure 1 ). StxA has no intrinsic capacity to cross membranes, and retro-translocation is achieved by subversion of another cellular process, in this case the proteintranslocation channel Sec61. 4 Sec61 is normally used for the secretion of newly synthesized proteins, as well as for transport of terminally misfolded host proteins from the ER lumen back into the cytosol, where they are ubiquitinated and targeted to the proteasome for degradation. Retrotranslocation of StxA via Sec61 involves interaction with two distinct ER chaperones, BiP and HEDJ/ERdj3, which may mistake a hydrophobic domain toward the C terminus of StxA for a terminally misfolded protein. 4 Presumably, retrotranslocated StxA escapes ubiquitination and degradation and is then free to interact with 28S ribosomal RNA.
Th e situation is markedly diff erent in monocytes/macrophages and related cell lines, which express Gb 3 on their surface and bind Stx, but are not susceptible to Stx-induced inhibition of protein synthesis. 5 In these cells, bound toxin-receptor complexes are internalized into early endosomes, but they do not become associated with lipid rafts or enter the retrograde pathway. Instead they fuse with late endosomes and are targeted to the lysosomes where the toxin is degraded (Figure 1 ). 4 Th is is not to say that Stx has no eff ect on monocytes/macrophages. On the contrary, Stx is known to activate the mitogen-activated protein kinase pathway, leading to nuclear translocation of nuclear factor-κB and production of cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6. 5, 6 Th is may be of importance during pathogenesis of Shiga toxigenic E. coli disease, because TNF-α is known to upregulate Gb 3 expression by microvascular endothelial cells, sensitizing commentar y them to Stx. What then determines the intracellular fate of Gb 3 -Stx complexes, and as a consequence the extent of cytotoxicity/activation? Clearly, association with lipid raft s is of pivotal importance, and this could be infl uenced by the fattyacyl moieties of diff erent Gb 3 isoforms. Other aspects of gross membrane composition -for example, cholesterol and glycosphingolipid content -may also be important. 2, 7 Notwithstanding the above, few studies have directly examined Stx traffi cking in cells that are targeted by the toxin in hemolytic-uremic syndrome, particularly those in the kidney. Warnier et al. 8 (this issue) have now examined traffi cking of StxB in human glomerular microvascular endothelial cells (GMVECs) and mesangial cells (MCs). Th ese cell types have previously been shown to express Gb 3 constitutively, and to upregulate it further after stimulation with TNF-α. Nevertheless, whether stimulated or not, both cell types were more resistant to Stx-mediated cytotoxicity than HeLa or Vero cells, although protein synthesis was still inhibited. 9, 10 Warnier et al. 8 used a combination of immunofl uorescence microscopy and biochemical techniques to demonstrate defi nitively that StxB does indeed undergo retrograde transport to the ER in both these primary cell types. Cy3-labeled StxB colocalized with the Golgi marker CTR433 within 4 hours of exposure, but was no longer detectable in the Golgi compartment aft er 24 hours. Th e authors then used a derivative of StxB carrying a tandem sulfation signal recognized by a trans-Golgi network-localized sulfotransferase. Th is enabled autoradiographic assessment of retrograde transport to the trans-Golgi network compartment by exposing GMVECs and MCs to the tagged StxB derivative in the presence of [ 35 S]sulfate. Arrival in the ER itself was confi rmed with the use of a diff erent StxB derivative with an N-glycosylation site introduced at its C terminus. Th is acted as a substrate for ER-localized oligosaccharyl transferase, and glycosylation of StxB (and, by inference, arrival in the ER) was evident from an electrophoretic mobility shift . Pre-labeling of the tagged StxB with 125 I enabled quantitative assessment of the extent of glycosylation, which was detectable in both GMVECs and MCs and was greater aft er 24 hours of incubation than at 4 hours. Approximately 7%-10% of total cell-associated StxB was glycosylated at the latter time point in both cell types. In both the sulfation and the glycosylation assays, the total amount of Stx transported was greater in cells that had been pre stimulated with TNF-α. However, this was directly attributable to increased expression of Gb 3 (and hence the total amount of StxB that bound to the cell surface), rather than to any eff ect of TNF-α on the effi ciency of retrograde transport.
Interestingly, the close correlation between Gb 3 expression and the total amount of StxB transported to the ER did not hold when GMVECs and MCs were compared with HeLa cells. Th e latter transported signifi cantly more StxB to the ER compartment, even though total Gb 3 levels were lower than in TNF-α-stimulated GMVECs or MCs. Increased retrograde transport is also consistent with the greater lethality of Stx holotoxin previously observed for cancer cell lines such as HeLa, compared with the primary human cells. Why should this be so? One possibility is that the various cell types express Gb 3 isoforms that diff er in their capacity to associate with lipid raft s, as suggested previously for monocytes/ macrophages versus HeLa cells. However, Warnier et al. 8 report that the total amounts of 125 I-StxB associating with the lipid raft fraction were similar between the three cell types. Th is suggests that there is some other fundamental diff erence in the effi ciency of the retrograde traffi cking system, perhaps the rate of vesicle recycling.
Of course, the susceptibility of a given cell type to Stx will also be aff ected by the efficiency of retro-translocation of the catalytic A 1 fragment across the ER membrane into the cytosol. Th is will directly infl uence the extent of damage infl icted on the protein synthesis machinery. A recent study 11 has shown that association of Stx with lipid raft s is important for this process as well, and that other membrane glycosphingolipids aff ect the partitioning of Stx into these functionally critical commentar y ER microdomains. It is noteworthy that certain ER proteins involved in the retrotranslocation process also partitioned into the lipid raft fraction. Further studies are needed to determine whether there are innate diff erences in the effi ciency of this final retro-translocation step between primary renal cells, such as GMVECs and MCs, and the more susceptible cell lines. Deficiency in either retrograde transport of Stx from the cell surface to the ER, or retro-translocation across the ER membrane into the cytosol, is likely to result in sublethal amounts of toxic StxA 1 entering the latter compartment, limiting ribosomal damage. In some cell types -for example, intestinal epithelial cells and human umbilical vein endothelial cells -sublethal toxin doses have been shown to elicit a so-called 'ribotoxic stress response, ' which is characterized by increased production of new ribo somes and proinfl ammatory cytokines. 12 Further research is needed to determine whether similar responses are elicited in renal cells such as GMVECs and MCs. This will throw further light on the relative contribution of direct Stx toxicity versus toxin-induced infl ammatory responses to the pathophysiology of hemolytic-uremic syndrome.
